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Transcription factors (TFs) are the primary mechanism that cells use to respond to external 
stimuli. These TFs allow for inducible regulation of gene expression. For this reason, TFs can act 
as a proto-oncogenes, tumor suppressors, or secondary messengers and aid many hallmarks of 
cancer. Understanding how TFs interact in cancer-causing pathways could lead to a much better 
understanding of the disease. In both the Guttridge and Miles laboratories, the impact of 
transcription factors in cancer-causing pathways, NF-κB in the former and RB in the latter, was 
investigated. Elucidating the function of lesser-known molecules in these pathways could 
profoundly impact how we understand the development of several different types of cancer. 
The NF-κB pathway plays an important role in controlling the immune response. It is also 
constitutively activated in leukemia/lymphoma, AML, breast, colon, pancreas, liver, head and 
neck cancers and is activated by many oncogenes (Ras, Her2/neu, BCR-ABL, HTLV-1/TAX and 
et al). In transformed cells, NF-κB is thought to suppress the immune system and allow for tumor 
development. 35 possible candidate genes were tested for NF-κB-regulation with qRT-PCR. 12 
of these genes showed differential gene expression between wild-type and mutant NF-κB cell 
lines, showing that they could be involved in immune suppression around cancer cells. 
The RB pathway, controlled by RB1, RBL1, and RBL2 genes, and the pocket proteins (pRB, 
p107, and p130) that these genes encode are critical for regulating E2Fs that promote cell 
proliferation and apoptosis. pRB is important tumor suppressor that is inactivated in almost all 
human cancers and E2F functions are also commonly mis-regulated in cancer. Retinoblastoma 
(RB), a rare tumor of the retina caused by the homozygous loss of RB1, is thought to originate in 
rod and cone retinal pigment epithelial (RPE) cells. 
Retinoblastoma susceptibility gene (RB1), which encodes pRB, was first tumor suppressor gene 
ever identified. However, the functions RBL1 and RBL2, which encode p107 and p130 
respectively, are still unknown despite encoding similarly structured proteins and having similar 
importance to the RB pathway as RB1. CRISPR-Cas9 gene editing was used to create two 
knockout (KO) RPE cell-lines for each RBL1 and RBL2. Western Blotting confirmed that both 
RBL2 cell lines were homozygous CRISPR-KOs while the RBL1 cell lines were a homozygous 
CRISPR-KO and a heterozygous CRISPR-KO.  
Introduction 
Cells must respond to external stimuli to develop and differentiate. The primary way that 
cells can modulate their gene expression profile to respond to these effects is via transcription 
factors (TF). These molecules bind to specific response elements (RE) in DNA promoter regions 
to either recruit RNA polymerases (Pol), including Pol II, or to bind to REs irreversibly 
(Latchman, 1997). As a result, TF binding to cis-regulatory DNA sequences can turn genes “on” 
or “off.” (Phillips et al, 2008). This inducible regulation of gene expression is a critical aspect of 
the ability of multicellular organisms to adapt to environmental, mechanical, chemical, and 
microbiological stresses (Hayden, M. S. et al, 2008). 
Transcription factors have a central role in cancer biology as they are capable of acting as 
a proto-oncogenes, tumor suppressors, or secondary messengers. Cancer is “the uncontrolled 
overgrowth of a particular cell type, initiated with an unwanted mutation in one or more genes, 
followed by an increasing accumulation of defects in hundreds if not thousands of genes, as a 
function of time, leading to invasive malignancy” (Bartek and Lukas, 2001). TFs play major 
supporting roles in cancer development, aiding many hallmarks of cancer: cell survival, cell 
growth, cell differentiation, proliferation, immune suppression, inflammation, and angiogenesis 
(Courtois et al, 2006) (Hamik et al, 2006). It is therefore unsurprising that TFs account for 20% 
of all oncogenes that have been discovered (Lambert et al, 2018). Given the overall importance 
of transcription factors to cancer development, discovering how TFs interact in cancer-causing 




The Nuclear Factor kappa-light-chain-enhancer of activated B cell (NF-κB) family of 
transcription factors is likely the most intensely researched TF family. Around 10% of all articles 
on PubMed about TFs are on NF-κB (Chaturvedi, M.M. et al, 2011), a rational development 
since the NF-κB pathway is a major mechanism used by the body to respond to stimuli. 
NF-κB regulates many functions including cell proliferation, cell survival, the cellular 
stress response, and inflammation (Courtois et al, 2006). In particular, this pathway plays an 
important role in controlling the immune response. NF-κB initially regulates the expression of 
genes during embryonic development, shaping the development of the mammary gland, bones, 
skin, and central nervous system (Hayden, M.S. et al, 2004). NF-κB regulates cytokines, growth 
factors, and effector enzymes in response to aspects of both innate and adaptive immunity 
(Hayden, M.S. et al, 2004). In the context of innate immunity, Toll-like receptor (TLR) signaling 
spurred on by a wide variety of pathogens can lead to activation of NF-κB and production of 
inflammatory proteins (Bonizzi et al, 2004). As an important aspect of adaptive immunity, 
antigen receptor binding leads to a signaling cascade that activates NF-κB activation and causes 
the release of cytokines that drive B-cell differentiation (Bonizzi et al, 2004). 
The NF-κB pathway [Figure 1] is activated via an IκB kinase (IKK) complex consisting 
of three subunits: inhibitor of nuclear factor kappa-B kinase subunit alpha (IκKα), inhibitor of 
nuclear factor kappa-B kinase subunit beta (IκKβ), and inhibitor of nuclear factor kappa-B kinase 
subunit gamma (IκKγ). This IΚK complex phosphorylates IκBα, which causes subsequent 
ubiquitination and degradation of the IκBα protein, thus releasing the p50/p65 dimer into the 
nucleus to activate transcription (Wang, J et al, 2009). 
Given the importance of NF-κB in many functions of healthy cells, it is unsurprising that 
the mis-regulation of the pathway can have damaging consequences. Mutations and/or epigenetic 
 
Figure 1: The Classical NF-κB pathway (Jost P. J. and Ruland J, 2007) 
alterations of the pathway have been implicated in many human and animal diseases, especially 
those associated with chronic inflammation, immunodeficiency or cancer (Courtois et al, 2006). 
NF-κB has anti-apoptotic activity, which usually aids the growth of the progenitors of immune 
cells, and can be used to enable replicative immortality of cancer cells (Hanson et al, 2004). 
Additionally, the inflammation response that NF-κB can induce could be used to promote tumor 
growth. Lastly, NF-κB normally functions as a tumor suppressor but can switch to tumor 
promoter during Ras-mediated transformation. This allows for the suppression of the immune 
system around tumor cells (Wang, D. J. et al, 2014). 
 
RB, RBL 1, and RBL 2 
The retinoblastoma susceptibility gene (RB1) was the first tumor suppressor gene to be 
identified (Friend et al, 1986). The protein it encodes, pRB, serves as a negative regulator of cell 
proliferation (van den Heuvel et al, 2008). As a negative regulator, pRB has a role in temporary 
and permanent cell cycle arrest, genomic stability, apoptosis and differentiation (Burkhart et al, 
2008). pRB is an important tumor suppressor that is inactivated, directly or indirectly, in almost 
all human cancers (Burkhart et al, 2008). 
The RB1 gene is part of a larger gene family that includes RB Transcriptional 
Corepressor Like 1 (RBL 1) and RB Transcriptional Corepressor Like 2 (RBL 2). These three 
genes encode structurally related “pocket proteins” pRb, p107, and p130, respectively (Di Fiore 
et al, 2013). pRB inhibits the E2 Promoter Binding Factor (E2F) proteins, transcription factors 
that promote the transcription of mRNAs involved in both cell proliferation and apoptosis (Miles 
et al, 2014). 
The E2F family of transcription factors activate genes that are necessary for the G1/S-
phase transition (van den Heuvel et al 2008). RB family proteins bind to E2Fs in a temporal 
fashion, inhibiting E2F transcriptional activities in the early G1 phase of the cell cycle. In late G1 
to S phase, cyclin-dependent kinases (CDKs) phosphorylate the RB family proteins, causing 
them to dissociate and freeing E2Fs to activate E2F-dependent transcription (Burkhart et al, 
2008). Like pRB, E2F transcription factor functions are commonly mis-regulated in cancer (Ji, 
J.Y. et al, 2012). 
The activities of E2F1-5 are negatively regulated by their specific interaction with pocket 
proteins (pRB, p107, p130) (Dimova et al, 2003). The E2F family is broken up into two 
subgroups: activator E2Fs and repressor E2Fs. Activator E2Fs are expressed at specific times in 
the cell cycle and promote cell cycle progression, while repressor E2Fs are expressed during the 
entirety the cell cycle but are specifically required for cell cycle exit and differentiation 
(Wikenheiser-Brokamp K.A, 2006).  
pRB is structurally related to p107 (encoded by RBL 1) and p130 (encoded by RBL 2) 
but the latter two pocket proteins are much more structurally related to one another than to pRB 
(Classon and Dyson, 2001). Additionally, p107 and p130 only associate with the repressor E2Fs, 
namely E2F4 and E2F5, while pRB binds primarily to activator E2Fs, like E2F1, E2F2, and 
E2F3a, as well as one repressor, E2F3b [Figure 2] (Cobrinik, 2005). 
 There are a few differences in expression among pRB, p130, and p107 in proliferating, 
nonproliferating and quiescent cells. pRB expression is seen in both proliferating and 
nonproliferating cells, p107 expression is most prominent in proliferating cells, and p130 
expression is primarily seen in arrested cells (Classon and Dyson, 2001). However, these 




I led my own project that used quantitative/real-time reverse transcription polymerase 
chain reaction (qRT-PCR) to explore candidate target genes for a cancer-causing pathway, NF-
κB. This project focused on measuring how NF-κB can function in cancer cells to counter 
immune elimination by the innate and adaptive immune systems. As a bona fide regulator of the 
immune response (Hayden, M.S. et al, 2004), NF-κB supports cancer development by promoting 
cell survival, cell growth, proliferation, metastasis, and epithelial to mesenchymal transition 
(EMT) (Chaturvedi, M.M. et al, 2011). 
NF-κB is also constitutively activated in several cancers or cancer cell lines 
(leukemia/lymphoma, acute myeloid leukemia, breast, colon, pancreas, liver, head and neck 
cancers) and is activated by many oncogenes (Ras, Her2/neu, BCR-ABL, HTLV-1/TAX). The 
NF-κB family of proteins function as dimers from 5 subunits, with the p50/p65 heterodimer 
being expressed in almost all mammalian cells (Wang, J et al, 2009). 
 
Figure 2: Interactions among the pocket proteins and members of the E2F family. pRB binds 
primarily to activators (E2F1, E2F2, E2F3a) as well as one repressor (E2F3b). p107 and p130 
only bind to repressor (E2F4, E2F5) (Cobrinik, 2005). 
The p65 subunit of NF-κB acts as a tumor suppressor in normal cells by sustaining 
senescence following DNA damage (Wang, J et al, 2009). However, recent findings from the 
Guttridge Lab reveal that, following immortalization, p65 switches to an oncogene by 
counteracting the surveillance properties of immune cells (Wang, D. J. et al, 2014). This would 
indicate that NF-κB can also function in cancer cells to counter anti-tumor immune cells. 
NF-κB exerts this effect by protecting transformed cells against macrophage-derived 
proapoptotic factors, tumor necrosis factor, and nitric oxide [Figure 3] (Wang, D. J. et al, 2014).  
Evidence for protection against macrophages is shown by a greater survival rate amongst cancer 
cells in wild-type cell lines relative to NF-κB null lines [Figure 4] (Wang, D. J. et al, 2014). 
Additionally, in severe combined immune deficiency (SCID) mice, tumor growth is much faster 
in wild type Ras cells than p65-/-Ras cells [Figure 5] (Wang, D. J. et al, 2014).   
Previous experiments conducted by researchers in the Guttridge Lab, comparing 
p65+/+Ras and p65-/-Ras Mouse Embryonic Fibroblasts (MEFs) by RNA sequencing, identified 
1,946 genes as being downregulated in p65-/-Ras cells (Ratnam et al, 2017). Once grouped based 
on their biological function, 51 were classified as genes that participate in cellular movement, 
secretion, enzyme production, and gene expression. The goal of this project was to discover all 
remaining unpublished target genes of NF-κB regulation to get an extensive view of how the NF-




My project is focused on the RB pathway, attempting to elucidate the roles of the RBL 1 
and RBL 2 genes. Retinoblastoma (RB), a rare tumor of the retina caused by the homozygous 
loss of RB1, is thought to originate in rod and cone retinal pigment epithelial (RPE) cells, (Xu X. 
L. et al, 2009). The subsequent loss of the RB1 protein, pRB, results in loss of E2F regulation, 
chromatin changes and developmental defects leading to tumor development (Elchuri et al, 
2018). 
With RB1 being a major regulator of multiple processes in a cell, pRB loss was expected 
to majorly change the cellular landscape – specifically, result in increased cellular proliferation. 
However, pRB-depletion in model organisms has only a small effect on accelerating growth 
rates. This was shown to be partly because of compensatory mechanisms by p107 and p130 (Xu 
X. L. et al, 2014).  
 
     Figure 5: Tumor growth 
among p65+/+Ras and p65-/- 
SCID mice. Data is from 16 
mice injected (p = 0.004). 
(Wang, D. J. et al, 2014) 
Figure 3: Model for NF-κB 
protection of tumor cells 
against macrophages 
(Wang, D. J. et al, 2014) 
 
Figure 4: NF-κB increases 
survival in higher effector to 
target ratios. Data is from 3 
experiments (p<0.001). 
(Wang, D. J. et al, 2014) 
* 
When either of these lesser-known pocket proteins are deficient in mouse models, there 
are massive phenotypic impacts. p107 null mutants (p107-/-) had increased neural progenitor cell 
proliferation and apoptosis, subtle thickening of long bones, impaired growth, and a 
myeloproliferative disorder while p130–/– mutants occasionally suffered lethality with aberrant 
neural, muscle and heart development (Cobrinik et al, 1996). p107-/-, p130–/– double mutants all 
suffered lethality at birth and had aberrant endochondral bone development, increased epidermal 
proliferation and aberrant differentiation, and delayed development of hair, whiskers and teeth 
(Cobrinik et al, 1996). Lastly, both pRb-/-, p107-/- and pRb-/-, p130-/- double mutants developed 
retinoblastoma and had enhanced apoptosis in the central nervous system (CNS) and liver 
(Dannenberg J. H. et al, 2004). 
The compensatory mechanisms shown in the presence of pRb-depletions, phenotypic 
changes seen in the absences of any pocket protein, and similarities in function among pRB, 
p107, and p130 still perpetuate the idea that both RBL 1 and RBL 2 function as tumor 
suppressors in the RB pathway. Despite the important role played by these proteins in the RB 
tumor suppressor pathway, the biological role of these proteins in normal human cell lines have 




Target gene search 
My project in the Guttridge Lab investigated the role of the 51 genes shown to participate 
in cellular movement, secretion, enzyme production, and gene expression pathways. These genes 
were further subjected to NF-κB regulated gene data base search (Gilmore et al, 2012). 16 genes 
were already published as NF-κB regulated genes, therefore these genes were eliminated from 
our study, leaving 35 as possible NF-κB target genes that were not previously reported. 
Primer design 
The mRNA sequences of each of the target genes in Mus Musculus were found using the 
National Center for Biotechnology Information (NCBI) gene database. Primers for each gene 
were designed with a web-based primer program from the mRNA sequence (primer 3.1). The 
most viable forward and reverse primers for each gene were checked for dimers based on 
complementary sequences within the mRNA sequence through Amplify. Primers for each gene 
target were ordered as 20 base-pair oligos from IDTDNA. Primers from IDTDNA were 
centrifuged then reconstituted to 100 uM with 100-200 uL ddH2O. These primers were further 
diluted 1:10 with 1-2 mL ddH2O. Lastly, the mixtures were put into primer plates and diluted on 
a 1:1 basis with ddH2O [Figure 6]. 
RNA Preparation 
RNA was then prepared from two independent lines of p65+/+Ras and p65-/-Ras MEFs. 
Adherent cells were cultured to 70 – 80% confluence and washed twice with ice cold Phosphate 
buffered saline (PBS). 1-3 mL Invitrogen TRIzol was added to each dish of cultured cells and the 
cells were scraped to one side of the dish. The suspensions were pipetted up and down several 
times to lyse the cells. 
These mixtures were incubated at room temperature for 5 minutes. 200 uL chloroform 
was then added to each 1 mL cell lysate. The mixtures were shaken vigorously for 15 seconds 
before incubation at room temperature for 2-3 minutes. These solutions were centrifuged at 
14000 rpm for 15 minutes. The supernatants were transferred to new tubes and the same volumes 
of isopropanol were added before mixture and incubation at room temperature for 10 minutes. 
The mixtures were then centrifuged at 14000 rpm for 10 minutes. 
 
Figure 6: Primer dilution plate; 5 uM (1 uL) of each primer was placed in six wells to be 
diluted then transferred onto a PCR plate 
The newest supernatants were poured off and 700 mL 75% ethanol was added before the 
tubes were inverted several times. The mixtures were then centrifuged at 14000 rpm for 10 
minutes and air dried for 15 – 20 minutes. The pellets were dissolved into DEPC-ddH2O and its 
OD was measured with a Thermo Scientific NanoDrop 2000 UV-Vis spectrophotometer to 
measure the Total RNA concentration. To confirm RNA purity and quality, 0.2-0.5 ug of each 
RNA was run on 1% TAE agarose gel (10 mL 1X TAE, 1 g agarose), which contained an RNA 
reference ladder with discrete ribosomal peaks of 28S, 18S and 5S, to be visualized on an 
Agilent 2100 Bioanalyzer. 
cDNA Preparation 
Half of this extracted RNA was further reverse transcribed into cDNA. 5 ug RNA was 
diluted with a mixture of ddH2O, 10 uL of basic primer (0.1ug/ul) diluted with oligodT 
(0.5ug/uL), and 1 uL of PCR specific primer for each gene tested. This mixture was incubated at 
70 oC for 10 minutes then room temperature for 5-10 minutes then on ice. It was mixed with 10 
uL 5x 1st strand buffer, 5 uL 0.1M DTT, 10 uL of 10mM dNTP, 2 uL Rnase inhibitor, 5-10 uL 
ddH2O (up to 48ul, dependent on initial concentration of RNA) and 2 uL M-MLV RTase. The 
solution was then gently vortexed and incubated in 37 oC water bath for 1 hour before another 
incubation at 70 oC for 10 minutes. It was put on ice for 2 minutes before being diluted with 
ddH2O so there was 10 – 20 ng of cDNA per uL. 
qRT-PCR analysis 
p65+/+Ras and p65-/-Ras (MEF) cDNA as well as p65+/+Ras and p65-/-Ras RNA [negative 
control for measure of purity] were subjected to real time quantitative PCR analysis in duplicate 
with SYBR Green PCR kits to test for differential expression and primer quality. Each gene 
sample was loaded into triplicate wells and mouse B-actin was used as the control. Every well 
contained 10 uL of 2X Roche SYBR Green PCR Master Mix, 6 uL ddH2O, 2 uL of (upstream 
and downstream) primer, and either 2 uL of p65+/+ cDNA, p65-/- cDNA, p65+/+ RNA, or p65-/- 
RNA [Figure 7]. 
This PCR plate was put into an Applied Biosystems StepOnePlus RT-PCR machine set at: 
Step 
Activation Amplification 
Hold denature annealing elongation 
Temperature 95°C 94°C 50-60°C 72°C 
Time 10min 15 sec 30 sec 20-60 sec 
Cycle - 35-45 
A comparison test was performed after the first qRT-PCR round using ΔCT and 
normalizing with a housekeeping gene in the MEF p65+/+ wells and p65-/- wells. The significance 
 
Figure 7: PCR plate; 2 uL from each well in the primer plate [Figure 6] was pipetted into the 
corresponding well of the PCR plate 
point for all genes was set to having expression on the p65-/- cDNA wells be less than or equal to 
70% of the expression on p65+/+ cDNA wells. 
A T-test was performed after the second qRT-PCR round. The intent was to use ΔCT and 
normalize with a housekeeping gene to compare the expression of each gene on three more wells 
of each p65+/+Ras and p65-/-Ras to see if any of the genes that these primers represent had 
differential expression between the wild-type and mutant strains. The significance point for all 
genes was set to having expression on the p65-/- cDNA wells be less than or equal to 70% of the 
expression on p65+/+ cDNA wells. 
 
Miles Laboratory 
Guide RNA Design 
My project in the Miles Lab involves the CRISPR-mediated knock out (KO) of RBL 1 
and RBL 2 genes in a normal human RPE1 cell line. I designed guides with ChopChop program 
from MIT and used these to order properly designed guide RNAs for the two genes (RBL 1 and 
RBL 2) that I am attempting to knockout of cell lines. Once received, these guides were 
reconstituted to 100 uM in H2O. 



















Vector was then midi-prepped with a QIAGEN midiprep kit for use in cloning. 2 mL of 
LB media, 2 uL ampicillin, and cells were picked from colonies of each cell line mixed together 
and incubated on a shaker (250 rpm) at 37 oC overnight. 2 mL of every mixture was then added 
to 48 mL of LB media each and incubated on a shaker (250 rpm) at 37 oC overnight. These 
cultures were harvested by centrifuging at 6000 g for 15 minutes at 4 oC. The pellets were 
resuspended in 4 mL of P1 buffer. 4 mL of P2 buffer was added and the solution was mixed by 
inversion and incubated at RT for 5 minutes. 4 mL of P3 buffer was then added, followed by 
inversion and incubation on ice for 15 minutes. The mixtures were centrifuged at 20,000 g for 30 
minutes at 4 oC. 
QIAGEN-tips were equilibrated with 4 mL QBT buffer then supernatants added to tips, 
entered resin by gravity flow. The tips were washed with 2 rounds of 10 mL QC buffer. DNA 
from each tip was eluted with 5 mL QF buffer into clean vessels. The DNA was then precipitated 
by adding 3.5 mL isopropanol and mixing. The mixtures were centrifuged at 20,000 g for 30 
minutes at 4 oC and the supernatants were decanted. The remaining DNA pellets were washed 
with 5 mL 70% ethanol and centrifuged at 20,000 g for 10 minutes and the supernatants were 
decanted. The final pellets were air-dried for 10 minutes then dissolved in 100 uL of endotoxin-
free TE. The vector DNA was digested with restriction enzymes by mixing 5 ug of DNA, 2.5 uL 
BsmB1, and 10 uL 10x NEB Buffer for each vector. The mixtures were incubated for 4 hours at 
37oC. 
The DNA was then treated through gel purification to isolate and purify DNA fragments 
based on size. Loading buffer was added to each of the DNA samples. The agarose gel was 
placed into the electrophoresis unit which was filled with 1x TAE until the gel was covered. A 
molecular weight ladder was loaded into the first lane of the gel while the DNA samples were 
loaded into the additional wells of the gel. The gel was placed in a BIO-RAD Wide Mini-Sub 
Cell GT, which was attached to a BIO-RAD Power Pac and run at 120 V then ramped up to 150 
V for 2 hours. DNA fragments were visualized with UV light. 
The DNA band was excised from the agarose gel using a QIAGEN QIAEX II Gel 
Extraction Kit. 3 volumes of QX1 buffer were added to 1 volume of gel. QIAEX II was 
resuspended by vortexing for 30 s and 30 µl of QIAEX II was added. The solution was incubated 
at 50°C for 10 min and mixed by vortexing every 2 min to keep QIAEX II in suspension. The 
sample was then centrifuged for 30 seconds and supernatant was removed. The pellet was 
washed with 500 µl of Buffer QX1 and resuspended by vortexing. It was centrifuged for 30 
seconds before all supernatant was removed. The pellet was then washed twice with 500 µl PE 
buffer. It was again resuspend by vortexing then centrifuged for 30 seconds before all 
supernatant was removed. This pellet was air-dried for 10–15 min, resuspended with 20 µl of 10 
mM TrisCl, and mixed by vortexing. This solution was incubated at 50°C for 5 minutes before 




After the vector was prepared, the cloning process began. 100 uM (2.62 uL) of forward 
and reverse guides were diluted with 44.76 uL of ddH2O for every gene. This mixture was run in 
a Thermocycler at 95 oC for 5 minutes then ramped down by 0.1 oC to 25 oC and allowed to sit 
until the next step. The annealed oligos were diluted 1:200 with ddH2O and incubated at room 
temperature for 1 hour. 
1 uL of the diluted oligo duplex, 5 uL 2x Electroligase buffer, 3.1 uL ddH2O, 0.9 uL of 
BsmBI digested Blast plasmid, and 1 uL Electroligase were mixed for each gene. The mixture 
was inactivated at 65 oC for 15 minutes in water bath. 2 uL of each mixture was put into 50 uL of 
Stbl3 competent cells. The solutions put into 2 mm cuvettes and pulsed in a BIO-RAD 
MicroPulser at the Ec2 (2.5 kV/pulse) setting. The shocked solutions were put into 1 mL of SOC 
and incubated in a shaker for 2 hours at 37 oC. They were then spun down at 6000 g for 3 
minutes and resuspended in 50 uL of SOC. Lastly, the solutions were plated on ampicillin plates 
and incubated at 37 oC overnight. 
2 mL of LB media, 2 uL ampicillin, and cells picked from colonies of each cell line were 
mixed together and incubated on a shaker (250 rpm) at 37 oC overnight. 2 mL of every mixture 




DNA was extracted from each of these cultures through a QIAGEN mini prep protocol. 
Pellets were harvested by centrifuging at 6000 g for 15 minutes at 4 oC then resuspended in 300 
uL of P1 buffer. 300 uL of P2 buffer was added to each of the solutions, which were mixed by 
inversion and incubated at 24 oC for 5 minutes. Next, 300 uL of P3 buffer was added and the 
solutions were mixed by inversion then incubation on ice for 5 minutes. The mixtures were 
centrifuged at 14,000 g for 10 minutes at 4 oC. 
In the mean-time, QIAGEN-tips were equilibrated with 1 mL QBT buffer. The 
supernatant of each solution was added to a tip and entered resin by gravity flow. The tips 
washed with 2 rounds of 2 mL QC buffer. DNA from each solution was eluted with 800 uL QF 
buffer into clean vessels. This DNA was precipitated by adding 560 uL isopropanol and mixing. 
The mixtures were centrifuged at 20,000 g for 30 minutes at 4 oC before their supernatants were 
decanted. The DNA pellets were washed with 1 mL 70% ethanol and centrifuged at 20,000 g for 
10 minutes before their supernatants were decanted. The final pellets were air-dried for 10 
minutes then dissolved in 20 uL of endotoxin-free TE. 
Sanger sequencing with the help of a hU6-F (5'-GAGGGCCTATTTCCCATGATT-3') 
primer was used to confirm the identities of the DNA extracted. 
 
DNA Extraction-Midiprep 
Positive clones containing guides RBL 1-1, RBL 1-2, RBL 2-1, and 2-2 were picked 
from each cell line. A positive clone, 2 mL of LB media, and 2 uL ampicillin were mixed 
together for each cell line and incubated on a shaker (250 rpm) at 37 oC overnight. 2 mL of every 
mixture was then added to 48 mL of LB media each and incubated on a shaker (250 rpm) at 37 
oC overnight. 
The cultures were harvested by spinning on a Thermo Scientific Sorvall Lynx 4000 
Centrifuge at 6000 g for 15 minutes at 4 oC before the supernatants were decanted. The pellets 
were resuspended in 4 mL of P1 buffer. 300 uL of P2 buffer was added to each of the solutions, 
which were mixed by inversion and incubated at 24 oC for 5 minutes. Next, 300 uL of P3 buffer 
was added and the solutions were mixed by inversion then incubation on ice for 15 minutes. The 
mixtures were centrifuged at 20,000 g for 30 minutes at 4 oC. 
In the mean-time, QIAGEN-tips were equilibrated with 4 mL QBT buffer. The 
supernatant of each solution was added to a tip and entered resin by gravity flow. The tips 
washed with 2 rounds of 10 mL QC buffer. DNA from each solution was eluted with 5 mL QF 
buffer into clean vessels. This DNA was precipitated by adding 3.5 mL isopropanol and mixing. 
The mixtures were centrifuged at 20,000 g for 30 minutes at 4 oC before their supernatants were 
decanted. The DNA pellets were washed with 5 mL 70% ethanol and centrifuged at 20,000 g for 
10 minutes before their supernatants were decanted. The final pellets were air-dried for 10 
minutes then dissolved in 100 uL of endotoxin-free TE. 
 
Lentivirus Packaging and Transfection 
When a substantial amount of DNA was extracted, a lenti virus was prepared and used to 
infect cells. 24 hours before transfection, 5x106 293T cells were plated with 8 mL of complete 
growth medium on four different 10 cm plates. The plates were incubated at 37 oC, 5% CO2 
overnight. 
Once the 293T cultures were 80-90% confluent, 7 ug of DNA was diluted with water to 












RBL 1-1 639.964 7 10.9 589.1 
RBL 1-2 917.749 7 7.6 592.4 
RBL 2-1 1160.25 7 6.0 594 
RBL 2-2 992.074 7 7.1 592.9 
For each of these plasmids, 600 uL of diluted DNA was added to a tube of Lenti-X 
Packaging Single Shots (X-fect Transfection Reagent, pVSVG plasmid, pDR9-81 plasmid) then 
vortexed for 20 seconds. The samples were incubated for 10 minutes at room temperature and 
centrifuged for 2 seconds. The solutions were then added to cell plates dropwise. These plates 
were incubated at 37 oC, 5% CO2 for 24 hours. 6 mL of complete growth medium was added to 
the plates before incubation at 37 oC, 5% CO2 for 48 hours. Lentiviral supernatants were 
collected at 48 hours and 72 hours after transfection. 
The viral supernatants were harvested with 0.45 um filter. 0.4 volumes of PEG/NaCl 
solution (30% PEG -8000/1.6MNaCl, 300 gm PEG, 93.5 gm NaCl per liter) was added to each 
mixture and they were incubated at -20 oC overnight. The mixtures were centrifuged at 2000 g 
for 30 minutes at 4 oC before supernatants were decanted. The pellets were resuspended in 2 mL 
full growth media (DMEM, 5% FBS, 1X penicillin/streptomycin) and stored at -80 oC in 1 mL 
aliquots. 
Viral Infection of cells 
24 hours before infection, RPE cells were plated in 12 wells with 1 mL of complete 
growth medium in each. 12 well-plate incubated at 37 oC, 5% CO2 overnight. 8 mL of complete 
growth medium was mixed with 8 uL of polybrene, a transfection reagent that neutralizes the 
charge repulsion between virions and a host cell’s surface to increase the efficiency of 
transduction. The previous media was removed from 6 of the wells and replaced with 1 mL of 
the complete growth medium and polybrene mixture. 40 uL of RBL 1-1 virus was added to well 
1, 40 uL of RBL 1-2 virus was added to well 2, 40 uL of RBL 2-1 virus was added to well 3, and 
40 uL of RBL 2-2 virus was added to well 4. This plate was centrifuged at 2500 rpm for 1 hour 
at 24 oC then incubated at 37 oC, 5% CO2 overnight. 
8 mL of complete growth medium was mixed with 16 uL of blastocyrin (BLAST). The 
previous media was removed from 6 of the wells and replaced with 1 mL of the complete growth 
medium and BLAST mixture. The media from these 6 wells were moved to a new 6 well plate 
which was incubated at 37 oC, 5% CO2 overnight. 
 
Protein Quantification 
The antibodies that would be used to confirm the RBL 1 and 2 KOs had to be tested in a 
Western blot. A plate was prepared with nine wells to quantify the amount of protein present in 
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B-Actin 0 0 0 0 0 0 2 
uL 
0 0 
P107 0 0 0 0 0 0 0 2 
uL 
0 
P130 0 0 0 0 0 0 0 0 2 uL 
 
294 uL of A buffer and 6 uL of B buffer were added to each well. The plate was put on a 
heat block at 95 oC for 5 minutes. A BCA assay was read at 562 nm. 
 
Western Blot Analysis of Antibodies 
Two 6% resolving gels were made by mixing 5.3 mLH2O, 2.0 mL 30% acrylamide, 2.5 
mL 1.5 M Tris, 100 uL 10% SDS, 100 uL 10% APS, and 8 uL TEMED. 1 mL Isopropanol was 
added to each gel to quench the reaction. A 4% stacking gel was made by mixing 3.05 mL H2O, 
1.25 mL protogel stacking buffer, 650 uL protogel, 25 uL 10% APS, and 5 uL TEMED. 1 mL 
Isopropanol was added to quench the reaction. 1X Tris Buffered Saline with Tween 20 (TBST) 
was made with 200 mL 10X Tris Buffered Saline (TBS), 1790 mL mL ddH2O, and 10 mL 
Tween 20. 
30 ug of each protein (RPE1 and RPE2) was mixed with 15-20 uL 
radioimmunoprecipitation assay (RIPA) buffer and 10 uL 3x loading buffer (LB) to get volume 
up to 30 uL. These samples were boiled for 4 minutes, placed on ice for 2 minutes, spun down, 
and loaded onto wells 1 and 2 of the gel. A molecular weight ladder (5 uL of BIO-RAD color 
marker, 5 uL of Invitrogen magic marker, 10 uL of 3x LB, 10 uL RIPA buffer) was added to 
well 3 of the gel. A BIO-RAD Power Pac was attached to the BIO-RAD Wide Mini-Sub Cell GT 
holding the gel and run at 120 V then ramped up to 150 V for 2 hours. 
A membrane was activated by putting it in about 5 mL TransBlot Turbo 1X buffer (200 
mL TransBlot Turbo 5X buffer, 200 mL 100% ethanol, and 600 mL ddH2O). The gel was placed 
on top of the activated membrane in a cassette of the TransBlot Turbo Transfer pack. The 
cassette was locked and placed in the TransBlot machine to run the transfer. Once the transfer 
was complete, membrane was placed in blocking buffer (5 g milk powder, 50 mL 1X TBST) and 
incubated on a shaker (250 rpm) at 37 oC overnight. 
The membrane was placed in 5 mL of wash buffer (0.5 g milk powder, 100 mL 1X 
TBST) for 15 minutes before the buffer was removed. 5 mL of wash buffer was added before 
incubation on a shaker (250 rpm) for 5 minutes then the buffer was removed, a process that was 
repeated. The membrane was then separated based on the molecular ladder into p107, p130, and 
β-actin sections. All sections were placed in separate sections in 4-5 mL of their respective 
primary antibodies diluted with wash buffer and incubated on a shaker (250 rpm) for 30 minutes. 
Primary Dilutions Volume Antibody (uL) Volume Wash Buffer 
(uL) 
B-Actin 1 5000 
P107 20 4000 
P130 20 4000 
First, 20 mL of wash buffer was added to membrane and quickly removed. High salt 
buffer (0.45 g of milk powder, 90 mL of TBST/0.5 NaCl solution) was then added to remove any 
primary antibodies that did not bind to protein from the membrane. The membrane was placed in 
5 mL of high salt buffer and incubated on a shaker (250 rpm) for 15 minutes before the buffer 
was removed. 5 mL of wash buffer was added before incubation on a shaker (250 rpm) for 5 
minutes then the buffer was removed, a process that was repeated. The membrane was then 
placed in 4-5 mL of secondary antibodies diluted with wash buffer and incubated on a shaker 
(250 rpm) for 30 minutes. 




B-Actin (mouse, Sigma Aldrich) 1 4000 
P107 (rabbit, GE Healthcare, 931V) 8 4000 
P130 (rabbit, GE Healthcare, 934V) 8 4000 
20 mL of wash buffer was added to the membrane and quickly removed. The membrane 
was then placed in 5 mL of high salt buffer and incubated on a shaker (250 rpm) for 15 minutes 
before the buffer was removed. 5 mL of wash buffer was added before incubation on a shaker 
(250 rpm) for 5 minutes then the buffer was removed, a process that was repeated twice. 1 mL of 
ECL buffer was added to membrane and then put in the Li-Cor machine to visualize bands. 
 
Western Blot Analysis of KOs 
After the antibodies were shown to be of good quality, the CRISPR-KO cells were tested 
with a Western blot. First, media was removed from each of the cell lines. The cells were washed 
in 1X PBS and placed on ice. The PBS was removed, and each cell line was mixed with 100 uL 
4% SDS before being placed on ice. Samples were sonicated with several pulses on setting 3 
then incubated on ice for 30 minutes. The samples were then centrifuged at 2000 g for 10 
minutes at 4 oC. 2 uL of each sample was taken for protein quantification and the rest of the 
samples were stored at -80 oC. 
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RBL 1-1 0 0 0 0 0 0 2 
uL 
0 0 0 
RBL 1-2 0 0 0 0 0 0 0 2 
uL 
0 0 
RBL 2-1 0 0 0 0 0 0 0 0 2 
uL 
0 
RBL 2-2 0 0 0 0 0 0 0 0 0 2 uL 
 
294 uL of A buffer and 6 uL of B buffer were added to each well. The plate was put on a 
heat block at 95 oC for 5 minutes. A BCA assay was read at 562 nm. Samples stored at -80 oC 
A 4–20% Mini-PROTEAN TGX™ Precast 15-well (15 uL) Protein Gel was loaded with 
a blank (70 mL RIPA buffer, 35 mL 3x LB buffer) in lanes 1 and 15, a color marker (15 uL of 
BIO-RAD color marker, 30 uL of blank) in lanes 2, 8, and 14, a magic marker (10 uL of 
Invitrogen magic marker, 20 uL of blank) in lanes 3 and 13, and samples in lanes 4-7 and 9-12. 
The samples were made up of: 




V 3x LB 
(uL) 
4 & 9 Fus 1 3.51 11.40 8.6 10 
5 & 10 Fus 2 3.94 10.15 9.85 10 
6 RBL 1-1 2.82 7.09 2.91 5 
7 RBL 1-2 2.8 7.14 2.86 5 
11 RBL 2-1 2.82 7.09 2.91 5 
12 RBL 2-2 2.8 7.14 2.86 5 
The samples were boiled for 4 minutes, placed on ice for 2 minutes, spun down, and 
loaded onto gel. A BIO-RAD Power Pac was attached to the BIO-RAD Wide Mini-Sub Cell GT 
holding the gel and run at 130 V then ramped up to 150 V for 2 hours. 
A membrane was activated by putting it in about 5 mL TransBlot Turbo 1X buffer. The 
gel was placed on top of the activated membrane in a cassette of the TransBlot Turbo Transfer 
pack. The cassette was locked and placed in the TransBlot machine to run the transfer. Once the 
transfer was complete, membrane was placed in blocking buffer and incubated on a shaker (250 
rpm) at 37 oC overnight. 
The membrane was placed in 5 mL of wash buffer for 15 minutes before the buffer was 
removed. 5 mL of wash buffer was added before incubation on a shaker (250 rpm) for 5 minutes 
then the buffer was removed, a process that was repeated. The membrane was then separated 
based on the molecular ladder [cuts at 250, 75, and 25 kB then on central CM for top section] 
into p107, p130, and β-actin sections. All sections were placed in separate sections in 2-4 mL 
[determined by the size of the partial membrane in the section] of their respective primary 
antibodies diluted with wash buffer and incubated on a shaker (250 rpm) for 90 minutes. 
Primary Dilutions Volume Antibody (uL) Volume Wash Buffer 
(uL) 
B-Actin 0.8 4000 
P107 10 2000 
P130 10 2000 
First, 7-14 mL of wash buffer was added to each section of the membrane and quickly 
removed. Each section of the membrane was then placed in 3.5-7 mL of high salt buffer and 
incubated on a shaker for 15 minutes before the buffer was removed. 2-4 mL of wash buffer was 
added to each before incubation on a shaker for 5 minutes then the buffer was removed, a 
process that was repeated. Each section of the membrane was then placed in 2-4 mL of 
secondary antibodies diluted with wash buffer and incubated on a shaker for 45 minutes. 




B-Actin (mouse, Sigma Aldrich) 1 4000 
P107 (rabbit, GE Healthcare UK, 
931V) 
4 2000 
P130 (rabbit, GE Healthcare UK, NA 
934V) 
4 2000 
7-14 mL of wash buffer was added to each section of the membrane and quickly 
removed. Each section of the membrane was then placed in 3.5-7 mL of high salt buffer and 
incubated on a shaker for 15 minutes before the buffer was removed. 2-4 mL of wash buffer was 
added to each well before incubation on a shaker for 5 minutes then the buffer was removed, a 
process that was repeated twice. 1 mL of ECL buffer was added to membrane and then put in the 




 The RNA, which had their OD readings done on the NanoDrop spectrophotometer, all 
had 260/280 ratios between 1.8 and 2.1, showing that they had high quality. The purity and 
quality of this RNA was further confirmed by the fact that discrete bands had shown at 28S, 18S, 
and 5S -matching the RNA reference ladder- when visualized in the Agilent Bioanalyzer. 
The results from the first round of qRT-PCR informed the rest of my project. Consistent 
melt curves [Figure 8] for all samples established that each contained quality primers. 
The amplification plots [Figure 9] from both qRT-PCR rounds show that genes start 
amplifying between cycle 20 and 24 based on the AT content of their primer. The more AT-rich 
a primer is, the quicker amplification starts as there is a parallel trend with melting temperature. 
 
 
Figure 8: Melt Curves of 6 primers 
 
Figure 9: Amplification Plots of 6 primers 
In cell lines containing NF-κB, genes of interest had considerably greater expression than 
those that lacked NF-κB. 
After the comparison test was performed, 16 of the 35 target genes showed differential 
expression (p<0.05), were deemed genes of interest moving forward and thus grouped together. 
After the student T-test was performed, 12 of the 35 target genes showed differential expression 
(p<0.05), were deemed genes of interest moving forward and again, and were grouped together. 
Six of these 12 differentially expressed genes had functions that seemed especially important in a 
cancer-causing pathway [Figure 10]. 
 
Figure 10: The differential (p < 0.05) expression between 6 of the 12 genes of interest. 5 of 
the 6 shown, CYT1 being the exclusion, have a p value <0.01.  
Miles Laboratory 
DNA extraction with a mini prep kit was successful, having decent yields of DNA 
(ng/uL) and read quality (260/280 ratio). 
Name 260 Raw 280 Raw 320 Raw 260 280 260/280 ng/µL 
RBL 1-1 0.197 0.16 0.104 0.087 0.053 1.659 87.169 
RBL 1-2 0.086 0.071 0.053 0.028 0.015 1.866 28.089 
RBL 2-1 0.358 0.221 0.055 0.296 0.161 1.832 295.743 
RBL 2-2 0.1 0.079 0.054 0.041 0.022 1.856 41.361 
Sanger sequencing from DNA extracted in the mini prep protocol confirmed the identities 
of each sample. The region that is not highlighted represents the plasmid, the green highlighted 
region is the consensus leader region of the guide, and the yellow highlighted region represents 
the specific DNA sequence of the guide. 













The western blot of the antibodies [Figure 11] that would test KOs showed that they 
would all have utility in upcoming tests of RBL 1 and 2 KOs. 
DNA extraction with a midi prep kit was successful, having decent yields of DNA 




280 Raw 320 Raw 260 280 260/280 ng/µL 
RBL 1-1 0.713 0.413 0.059 0.64 0.346 1.848 639.964 
RBL 1-2 0.999 0.574 0.06 0.918 0.503 1.826 917.749 
RBL 2-1 1.23 0.692 0.054 1.16 0.63 1.843 1160.25 
RBL 2-2 1.069 0.607 0.061 0.992 0.538 1.845 992.074 
 
293T cells [Figure 12], visualized by an EVOS™ XL Core Imaging System, were used in 
conjunction with lentivirus because they allow for mass transfection. 
 
Figure 11: The validation of the primary and secondary antibodies for RBL 1 & RBL 2 
testing 
P107-1º Ab -1:200
Anti-Rabbit- 2º Ab – 1:500
P130-1º Ab -1:200
Anti-Rabbit- 2º Ab – 1:500
β-Actin -1º Ab -1:5000
Anti-Mouse- 2º Ab – 1:4000
RPE cells [Figure 13], visualized by an EVOS™ XL Core Imaging System, were used 
 
Figure 12: 293T Cells used during transfection with lentivirus 
 
Figure 13: RPE cells that were infected with viral supernatant later used during selection of 
CRISPR-KO cell lines  
because they are one of the only cell lines with an intact RB/E2F pathway. This allowed the 
Western Blot to show the true impact of RBL 1 & RBL 2 KOs. 
The Western Blot of the CRISPR-KOs [Figure 14] compared either the expression of 
p107 (for RBL 1 KOs) or p130 (for RBL 2 KOs) among the KOs and two negative CRISPR 
control cell lines (Fus 1 and Fus 2) with intact RBL 1 and RBL 2 genes. It standardized all the 
cell lines against a loading control (β-actin). All KOs had differential protein expression from the 
Fus cell lines, with RBL 1-1 appearing to be a successful KO of RBL 1 in addition to both RBL 




Figure 14: Western Blot was run comparing the expression of β-actin and either p107 or p130 




































Primers were designed that were able to confirm differentially regulated genes. With 
successful amplifications in the first round of PCR analysis, I identified 16 differentially 
regulated genes that had not been previously reported as being regulated by NF-κB. The second 
round of PCR analysis revealed that 12 genes of interest had significant differential regulation in 
NF-κB wild-type and mutant cell lines. In conclusion, I was able to narrow 35 genes encoding 
secreted factors to 12 possible NF-κB regulated genes.  
Future experiments will be performed to further analyze these genes to better understand 
how NF-κB can contribute to cancer development through cell survival, cell growth or immune 
suppression. If the way that the NF-κB pathway specifically helps cancer cells evade the immune 
system becomes clearer, a novel cancer therapy can be created to counter this mechanism and 
inhibit the entire pathway. A therapy of this nature could affect rapidly progressing cancers since 
constitutively active cancer cells appear to have a “NF-κB addiction” (Chaturvedi M.M., 2011). 
The first step to understand how these genes of interest can contribute to a cancer-causing 
pathway will be to test them in a cancer cell line where NF-κB is constitutively activated. 
Differentially expressed genes will be analyzed with RNA prepared from the cell lines of 
pancreatic cancer-afflicted mice with successful primers. The experiment will be run in triplicate, 
and t tests will be utilized to further confirm the statistical difference between p65+/+Ras and 
p65-/-Ras lines derived from KRasG12D; p53–/–; Pdx-Cre+/– (F) cell lines. After this, NF-κB 
binding sites will be investigated for each of the genes of interest on the rVista database to view 
how gene may be regulated within the pathway. The electrophoretic mobility shift assay 
(EMSA), chromatin immunoprecipitation (ChIP) and luciferase assay method can then be 
utilized to confirm NF-κB regulation of these genes. Additionally, an exploration will be made 
on the National Institute of Health’s The Cancer Genome Atlas (TCGA) to determine how the 
expression of genes of interest in different cancer patients predicts patient outcomes (survival). 
This will be necessary to see how these genes’ functions may change in different cancerous 
environments. Lastly, a knock-down or knock-out of these genes will be made in human cells to 
see if either can affect tumor development in tumor models. With all this information, one would 
be able to extrapolate signal transduction pathways to further understand how any certain gene is 
contributing to a cancerous environment. 
Miles Laboratory 
Three cell lines (RBL 1-1, RBL 2-1, RBL 2-2) were created that performed as phenotypic 
KOs of the gene they were specified for with CRISPR-Cas9 gene editing. This is important as a 
clone can be selected from any of these lines to eventually create bonafide RBL 1 or RBL 2 KO 
cell lineages that can be tested a multitude of times to understand the function of these genes, and 
their proteins, in the human body. Once the impact of these KOs is understood, they can act as a 
model for how p107 or p130 can act in a cancer-causing pathway as well. The fourth cell line, 
RBL 1-2, also serves as a partial knockdown and could conceivably contain a good enough KO 
clone to spawn its own RBL 1 KO lineage. 
In the future, KO clones will be selected, and western blots will be run to confirm KO of 
RBL 1 and RBL 2. At least two clones will be cultured for RBL 1 and RBL 2 each to ensure that 
the changes observed are not due to off-target effects. KO cell lines will be further characterized 
by functional and high throughput assays to determine the function of RBL proteins.  
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